title: Lipoprotein pattern in end-stage renal disease and following successful renal transplantation.
abstract: Lipoprotein abnormalities are common in uremia and frequently persist after successful renal transplantation (RT). Based on the influence of immunosuppression on lipoprotein metabolism, this prospective study in 76 patients has been focused on lipoprotein pattern in end-stage renal disease and after successful RT during a follow-up period of 18 months. Additionally, the influence of different immunosuppressive regimes has been evaluated. Hyperlipidemia was present in 32% of the patients before and in 59% after grafting. Total cholesterol was 5.42 +/- 1.57 mmol/l (mean S D) before RT and continuously and significantly increased during the entire observation period, being highest 18 months after RT (6.8 +/- 1.63 mmol/l; p < 0.01). This was mainly due to an increase in LDL-cholesterol (before RT: 3.68 (1.41 mmol/l; 18 months after RT: 4.69 +/- 1.88 mmol/l; p < 0.05) while HDL-cholesterol values only slightly increased (before RT: 0.99 +/- 0.36 mmol/l; 18 months after RT: 1.13 +/- 0.3 mmol/l; p < 0.05). Changes in total HDL-cholesterol were mainly due to an increase in HDL 3, while HDL 2 moderately increasing remained at low concentrations. As corticosteroid dosage was substantially reduced during the entire observation period, other factors such as cyclosporin A have to be considered for hyperlipidemia in renal transplant recipients. The observation on LDL-cholesterol being highest 18 months after transplantation suggests lipid lowering interventions to be indicated and might improve long-term outcome in renal transplant recipients.
authors.affiliation: Department of Internal Medicine III, University Hospital of Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Banyai-Falger
authors.forename: M
authors.initials: M
authors.lastname: Gottsauner-Wolf
authors.forename: E
authors.initials: E
authors.lastname: Stepan
authors.forename: W
authors.initials: W
authors.lastname: Strobl
authors.forename: M
authors.initials: M
authors.lastname: Jansen
authors.forename: G
authors.initials: G
authors.lastname: Heinz
authors.forename: W H
authors.initials: WH
authors.lastname: Hörl
authors.forename: K
authors.initials: K
authors.lastname: Derfler
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D016572:Cyclosporine / Q000494:pharmacology; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology; D006085:Graft Survival; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000601:surgery*; D016030:Kidney Transplantation / Q000502:physiology*; D008074:Lipoproteins / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D008074:Lipoproteins; D016572:Cyclosporine